Despite the differences in hyperglycemia incidence and management in SOLAR-1, similar median PFS was observed among high- and low-risk patients with PIK3CA mutations treated with alpelisib + fulvestrant (median PFS, 11.0 vs 10.9 months; HR, 1.097; 95% CI, 0.733–1.641). The gene discussed is PIK3CA; the disease is Hyperglycemia.